8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 1, 2008

ThermoGenesis Corp.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	333-82900	94-3018487
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
2711 Citrus Rd., Rancho Cordova, California		95742
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 916-858-5100

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 1, 2008, the Board of Directors of ThermoGenesis Corp. (the "Company") increased the number of board members to six (6), and elected Ms. Tiffany Olson as a new member of the Board of Directors of the Company. Ms. Olson is expected to be appointed to one or more committees of the Board at future meetings, but currently serves on no committee.

Ms. Olson, a director at Community Hospital Network and Simon Youth Foundation, is the former President & CEO of Roche Diagnostics Corporation, where she led North American (U.S. & Canada) commercial operations with P&L responsibility for over $1 billion in revenue and 2,500 employees. Prior to her President & CEO position, she held several positions with Roche from 1997 until she resigned in May 2008. Before joining Roche Diagnostics, Ms. Olson was the owner of Resource Consulting Services, a healthcare market research and new venture project management business. Among her accomplishments, she was instrumental in starting a non-profit association in the hearing-health industry, which provided market research spanning over 4,000 consumers. She also spent a number of years in leading positions with other healthcare providers. Ms. Olson holds an MBA from the University of St. Thomas (St. Paul, Minnesota) and a BS in Business from the University of Minnesota, School of Management. Most recently she was recognized by the Indianapolis Business Journal, as being a 2007 "Influential Women" in Indianapolis, Indiana.

Ms. Olson will receive an annual board retainer of $24,000 paid quarterly. Ms. Olson will also be awarded an option to purchase 25,000 shares of the Company's common stock, which will vest in three equal installments on August 1, 2009, 2010 and 2011, and will receive $1,500 per board meeting attended.

There are no related party transactions between Ms. Olson and the Company, or with management, and there are no arrangements or understandings between Ms. Olson with respect to her appointment, except for normal board compensation as disclosed.

Item 9.01 Financial Statements and Exhibits.

Press release dated August 6, 2008, titled "ThermoGenesis Corp. Names Tiffany Olson to Board of Directors".

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ThermoGenesis Corp.
August 6, 2008	By:	Matthew T. Plavan
		Name: Matthew T. Plavan
		Title: Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99	THERMOGENESIS NAMES TIFFANY OLSON TO BOARD OF DIRECTORS

EX-99

THERMOGENESIS NAMES TIFFANY OLSON TO BOARD OF DIRECTORS

FORMER HEAD OF ROCHE DIAGNOSTICS, NORTH AMERICA, HAS 25 YEARS OF LIFE SCIENCES INDUSTRY
EXPERIENCE

(RANCHO CORDOVA, CA), August 6, 2008—ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products that process and store adult stem cells, said today that Tiffany P. Olson, formerly President and Chief Executive Officer, Roche Diagnostics Corporation, North America, has been named to the Company’s Board of Directors. Her appointment brings the Company’s number of directors to six.

Olson, who has more than 25 years of healthcare industry experience, led the over one billion dollar operation for Roche Diagnostics Corporation for three years. Roche Diagnostics is a world-leader in in-vitro diagnostics and specializes in products and services for the molecular, chemistry, immunology, point-of care and life sciences markets. She joined Roche in 1997 and her positions also included Global Market Development and Quality, Vice President, Molecular Diagnostics, United States and other senior positions.

“Tiffany’s appointment is emblematic of our initiative to elevate both the Board of Directors and management team at ThermoGenesis. Her extensive experience in key areas of the healthcare industry will provide us invaluable insight as we pursue our growth strategies in that market,” said Dr. William Osgood, Chief Executive Officer of ThermoGenesis.

“This is an exciting time to be associated with ThermoGenesis. It is building upon its already strong position in regenerative medicine through developments such as the recent FDA authorization of its MarrowXpress™ and I look forward to working with the management team,” Olson commented.

Olson holds a B.S. in Business from the University of Minnesota School of Management and an MBA from the University of St. Thomas in St. Paul, Minnesota.

About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

• The BioArchive^® System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.

• AXP™ AutoXpress Platform (AXP™) is a proprietary family of automated devices that includes the AXP and the MarrowXpressä and companion sterile blood processing disposable for harvesting stem cells in a closed system. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MarrowXpress is used for isolating stem cells from bone marrow. ThermoGenesis sells the MarrowXpress directly to global customers.

• The CryoSeal^® FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

• The Thrombin Processing Device^TM (TPD™) is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of plasma in less than 30 minutes. The CE-Marked TPD is currently being marketed in Europe by Biomet, Inc., subsidiary Biomet Biologics, Medtronic, Inc. and independent distributors.

This press release contains forward-looking statements, and such statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
These statements involve risks and uncertainties that could cause actual outcomes to differ
materially from those contemplated by the forward-looking statements. Several factors, including
timing of FDA approvals, changes in customer forecasts, our failure to meet customers’ purchase
order and quality requirements, supply shortages, production delays, changes in the markets for
customers’ products, introduction timing and acceptance of our new products scheduled for fiscal
year 2009, and introduction of competitive products and other factors beyond our control, could
result in a materially different revenue outcome and/or in our failure to achieve the revenue
levels we expect for fiscal 2009. A more complete description of these and other risks that could
cause actual events to differ from the outcomes predicted by our forward-looking statements is set
forth under the caption “Risk Factors” in our annual report on Form 10-K and other reports we file
with the Securities and Exchange Commission from time to time, and you should consider each of
those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com

- End -